Anika Therapeutics, Inc. Provides Revenue Guidance for the Fiscal Year 2022
August 03, 2022 at 04:05 pm EDT
Share
Anika Therapeutics, Inc. provided revenue guidance for the fiscal year 2022. For the year, the company expects overall revenue to be toward the upper end of its guidance range of low to mid-single digit percent growth compared with 2021.
Anika Therapeutics, Inc. is a joint preservation company focused on developing, manufacturing, and commercializing products based on hyaluronic acid (HA) technology platform. The OA Pain Management product family consists of Monovisc and Orthovisc that provides pain relief from osteoarthritis conditions and Cingal consisting of its cross-linked HA material combined with a fast-acting steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products: Integrity, Tactoset, and Hyalofast; its line of sports medicine solutions repairs and reconstructs damaged ligaments and tendons, and its Arthrosurface portfolio of bone preserving joint technologies, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants. Its Non-Orthopedic product family provides orthopedic applications, including adhesion barrier product, advanced wound care products, and ear, nose and throat products.
ANIKA THERAPEUTICS, INC. 
